NTP42 Shows ‘Synergistic’ Potential to Treat PAH as Combo Therapy, Study Suggests
Combined with sildenafil, the potential therapy NTP42 eased symptoms of pulmonary arterial hypertension (PAH) in a rat model of the disease, a study reported. Further testing with other approved treatments is warranted, its researchers wrote, as the paired treatment showed more benefit than either sildenafil (sold as Revatio,…